<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303520</url>
  </required_header>
  <id_info>
    <org_study_id>Anti-CD19/CD22 CAR-T</org_study_id>
    <nct_id>NCT04303520</nct_id>
  </id_info>
  <brief_title>Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL</brief_title>
  <official_title>A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hrain Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/CD22
      bispecific chimeric antigen receptors (CARs) T cell therapy for CD19-positive Acute
      Lymphoblastic Leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

      1. To determine the feasibility ad safety of anti-CD19/ CD22 CAR-T cells in treating patients
      with CD19-positive Acute Lymphoblastic Leukemia.

      Secondary Objectives

        1. To determine in vivo expression, dynamics and persistency of anti-CD19/CD22 CAR-T cells.

        2. To determine in vivo expression of CD19-positive B cells.

        3. To access the complete remission rate (ORR) in patients with ALL with 3 months after
           CD19/CD22 CAR-T cells infusion.

        4. To investigate the favorable CD19/CD22 CAR-T cells dose and dosage regimen for the Phase
           II Clinical Trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CAR-positive T cells in circulation</measure>
    <time_frame>6 months</time_frame>
    <description>Duration of CAR-positive T cells in circulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of CAR-positive T cells infiltrated into lymphoma tissue</measure>
    <time_frame>6 months</time_frame>
    <description>Total number of CAR-positive T cells infiltrated into lymphoma tissue</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>CD19-positive ALL</condition>
  <arm_group>
    <arm_group_label>anti-CD19/CD22 CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration with anti-CD19/CD22 CAR-T cells in the CD19-positive ALL patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD19/CD22 CAR-T cells</intervention_name>
    <description>Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs</description>
    <arm_group_label>anti-CD19/CD22 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m2/d</description>
    <arm_group_label>anti-CD19/CD22 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>500mg/m2/d</description>
    <arm_group_label>anti-CD19/CD22 CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 13 Years to 70 Years, Male and female;

          2. Expected survival &gt; 12 weeks;

          3. Clinical performance status of ECOG score 0-2;

          4. Histologically confirmed as CD19-positive lymphoma and who meet one of the following
             conditions:

               -  Patients received at least 2 prior combination chemotherapy regimens (not
                  including single agent monoclonal antibody therapy) and fail to achieve CR; or
                  have disease recurrence; or not eligible for allogeneic stem cell
                  transplantation; or disease responding or stable after most recent therapy but
                  refused further treatment;

               -  Disease recurrence after stem cell transplantation.

          5. Accessible to intravenous injection, and no white blood cell collection
             contraindications

          6. Patients who meet the following conditions:

               -  Creatinine &lt; 2.5 mmol/l;

               -  Cardiac ejection fraction&gt;50%, no pericardial effusion and no pleural effusion
                  (ECHO examination);

               -  Baseline oxygen saturation&gt;92%;

               -  Total bilirubin≤1.5xULN;

               -  ALT/AST≤2.5x normal.

          7. Able to understand and sign the Informed Consent Document.

        Exclusion Criteria:

          1. Accompanied by other malignant tumor

          2. Active hepatitis B, hepatitis C, syphilis, HIV infection

          3. Suffering severe cardiovascular or respiratory disease

          4. Any other diseases could affect the outcome of this trial

          5. Any affairs could affect the safety of the subjects or outcome of this trial

          6. Pregnant or lactating women, or patients who plan to be pregnancy during or after
             treatment

          7. Occurrence of infection uncontrolled or requiring systemic treatment 14 days prior to
             assignment

          8. Patients who are accounted by researchers to be not appropriate for this test

          9. Received CAR-T treatment or other gene therapies before assignment

         10. Patients with symptoms of central nervous system

         11. Subject suffering disease affects the understanding of informed consent or comply with
             study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Henan Province of TCM</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi Cheng, M.D.</last_name>
      <phone>+(86)-139-3852-6995</phone>
      <email>clinicaltrials.chengzhi@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Litzow MR. Hematology clinic. Acute lymphoblastic leukemia. Hematology. 2014 Jun;19(4):246-7. doi: 10.1179/1024533214Z.000000000281.</citation>
    <PMID>24856441</PMID>
  </reference>
  <reference>
    <citation>Gökbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Hüttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012 Sep 6;120(10):2032-41. Epub 2012 Apr 4.</citation>
    <PMID>22493293</PMID>
  </reference>
  <reference>
    <citation>Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995 Dec 7;333(23):1540-5.</citation>
    <PMID>7477169</PMID>
  </reference>
  <reference>
    <citation>Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML; Children's Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008 Dec;22(12):2142-50. doi: 10.1038/leu.2008.251. Epub 2008 Sep 25.</citation>
    <PMID>18818707</PMID>
  </reference>
  <reference>
    <citation>Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013 May;14(6):e205-17. doi: 10.1016/S1470-2045(12)70580-6. Review.</citation>
    <PMID>23639321</PMID>
  </reference>
  <reference>
    <citation>Raetz EA, Bhatla T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematology Am Soc Hematol Educ Program. 2012;2012:129-36. doi: 10.1182/asheducation-2012.1.129. Review.</citation>
    <PMID>23233571</PMID>
  </reference>
  <reference>
    <citation>Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood. 1988 Jan;71(1):13-29.</citation>
    <PMID>3257143</PMID>
  </reference>
  <reference>
    <citation>Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. Am J Cancer Res. 2016 Jan 15;6(2):403-24. eCollection 2016. Review.</citation>
    <PMID>27186412</PMID>
  </reference>
  <reference>
    <citation>Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016;67:165-83. doi: 10.1146/annurev-med-051914-021702. Epub 2015 Aug 26. Review.</citation>
    <PMID>26332003</PMID>
  </reference>
  <reference>
    <citation>Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13.</citation>
    <PMID>28408462</PMID>
  </reference>
  <reference>
    <citation>Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.</citation>
    <PMID>27111235</PMID>
  </reference>
  <reference>
    <citation>Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20. Review.</citation>
    <PMID>27207800</PMID>
  </reference>
  <reference>
    <citation>Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.</citation>
    <PMID>25319501</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

